Metabolomics facilitates the discrimination of the specific and-cancer effects of free and polymer conjugated doxorubicin in breast cancer models

Autores de CIPF

• 

  Ana Armiñan De Benito

  Autor

• Martina Palomino Schatzlein

  Autor

• Coralie Deladriere

  Autor

• Juan José Arroyo Crespo

  Autor

• Sonia Vicente-Ruiz Salvador

  Autor

• 

  Maria Jesus Vicent Docon

  Autor

• Antonio Pineda Lucena

  Autor

Grupos de Investigación

• Laboratorio de Polímeros Terapéuticos

  

  Jefe/a de Grupo

  Maria Jesus Vicent Docon

Abstract

Metabolomics is becoming a relevant tool for understanding the molecular mechanisms involved in the response to new drug delivery systems. The applicability of this experimental approach to cell cultures and animal models makes metabolomics a useful tool for establishing direct connections between in vitro and in vivo data, thus providing a reliable platform for the characterization of chemotherapeutic agents. Herein, we used metabolomic profiles based on nuclear magnetic resonance (NMR) spectroscopy to evaluate the biochemical pathways involved in the response to a chemotherapeutic anthracycline drug (Doxorubicin, Dox) and an N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-conjugated form (HPMA-Dox) in an in vitro cell culture model and an in vivo orthotopic breast cancer model. We also used protein expression and flow cytometry studies to obtain a better coverage of the biochemical alterations associated with the administration of these compounds. The overall analysis revealed that polymer conjugation leads to increased apoptosis, reduced glycolysis, and reduced levels of phospholipids when compared to the free chemotherapeutic drug. Our results represent a first step in the application of integrated in vitro and in vivo metabolomic studies to the evaluation of drug delivery systems. (C) 2018 The Authors. Published by Elsevier Ltd.

Keywords

• Metabolomics; NMR; Nanomedicine; Polymer therapeutics; Breast cancer